⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835739 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL8090690 | 0.82 | — | — | |
| SCHEMBL8817556 | 0.81 | — | — | |
| SCHEMBL7843322 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL8090706 | 0.80 | — | — | |
| SCHEMBL8316259 | 0.78 | — | — | |
| SCHEMBL8098204 | 0.78 | — | — | |
| SCHEMBL8318160 | 0.77 | — | — | |
| SCHEMBL7411718 | 0.77 | — | — | |
| SCHEMBL20694086 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820455-B1 | 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2001-10-31 | — | — | EP | disclosed |
| US-6057454-A | USEFUL FOR TREATING OR PREVENTING ALL ISCHAEMIAS (SUCH AS FOCAL OR GLOBAL ISCHAEMIA) RESULTING FROM CEREBROVASCULAR DISORDERS | RHONE-POULENC RORER S.A. (FR) | 2000-05-02 | — | — | US | disclosed |
| EP-0820455-A1 | 5H, 10H-IMIDAZO [1,2-a]INDENO [1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | Aventis Pharma S.A. (FR) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031511-A1 | 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONE DERIVATIVES, PREPARATION THEREOF, AND DRUGS CONTAINING SAID DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1996-10-10 | — | — | WO | disclosed |